Henri Lichenstein, PhD

Dr. Lichenstein has served as Board member for CSC-SCT since 2007.   Dr. Lichenstein currently serves as Chief Scientific Officer at BioPontis Alliance. Prior to joining BioPontis in 2011, Henri had over 20 years drug development experience at Amgen, CuraGen Corporation and TopoTarget.  At CuraGen and TopoTarget, respectively, Henri served as Vice President of Product Development and Chief Development Officer, leading alliances with other companies and the National Cancer Institute in the global clinical development of a broadly active anti-cancer agent, belinostat in 20+ Oncology trials. He has also led drug discovery and development efforts for a number of other protein and monoclonal antibody therapeutics in Oncology and other disease areas, and has led corporate development in- and out-licensing initiatives. Dr. Lichenstein has a Ph.D. in Biochemistry and Molecular Biology from the University of California, Santa Barbara and is co-author and inventor on approximately 50 publications and 30 patents.